Becker's Healthcare November 26, 2024
Elizabeth Gregerson

GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.

Analysis for the study was conducted by national and international researchers from the U.S., Australia, U.K., Canada, Denmark and Germany.

Researchers compiled trial data from before March 26 on MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for their analysis. To be included in the study, trials must have had at least 500 participants with Type 2 diabetes, compared a GLP-1 medication to a placebo with 12 months of follow-up and reported cardiovascular or kidney related outcomes.

Here are five things to know from the study:

  1. Eleven...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Share This Article